Table 1 Demographic and clinical characteristics of the study participants (n = 26)
Age (years) – mean ± SD | 53.7 ± 9.6 |
Skin color – n (%) | |
white | 24 (92.3) |
brown | 1 (3.8) |
black | 1 (3.8) |
Level of education – mean ± SD | |
Incomplete primary education | 1 (3.8) |
Completed primary education | 7 (26.9) |
Completed secondary education | 13 (50.0) |
Completed higher education | 5 (19.2) |
Family history of breast cancer – mean ± SD | |
No | 11 (44.0) |
Yes | 14 (56.0) |
Breast cancer molecular subtype – mean ± SD | |
Luminal A (ER + or PR+/HER2-/Ki-67 < 14%) | 3 (12.0) |
Luminal B (ER + or PR+/HER2-/Ki-67 ≥ 14%) | 9 (36.0) |
Luminal HER* (ER + or PR+/HER2+) | 4 (16.0) |
HER2+ (ER- and PR-/HER2+) | 1 (4.0) |
Triple negative (ER-/PR-/HER2-) | 8 (32.0) |
Family history of CVD – mean ± SD | |
No | 8 (30.8) |
Yes | 18 (69.2) |
BMI (kg/m2) – mean ± SD | 29.85 ± 7.85 |
Comorbidities – n (%) | |
Arterial hypertension | 13 (50.0) |
Type 2 diabetes mellitus | 4 (15.4) |
Dyslipidemia | 2 (7.7) |
CV drug use – n (%) | |
Antihypertensive agents | 13 (50) |
Diuretics | 6 (23) |
Anticoagulant agents | 3 (11.5) |
Statins | 6 (23) |
Antidiabetic agents | 4 (15.3) |
Smoking status† – n (%) | |
Never smoked | 22 (84.6) |
Former smoker | 1 (3.8) |
Current smoker | 3 (11.5) |
Sedentary lifestyle – n (%) | |
No | 3 (11.5) |
Yes | 23 (88.5) |
Excessive alcohol use† – n (%) | |
No | 24 (92.3) |
Yes | 2 (7.7) |
Menopausal status – n (%) | |
Premenopausal | 8 (30.8) |
Postmenopausal | 18 (69.2) |
Type of treatment – n (%) | |
Adjuvant | 10 (38.5) |
Neoadjuvant | 16 (61.5) |
Other type of treatment‡ – n (%) | |
Radiotherapy (No/Yes) | 21 (84.0) / 5 (19.2) |
Endocrine therapy + trastuzumabe (No/Yes) | 22 (84.6) / 4 (15.4) |
Total cumulative dose of DOX – mean ± SD | 408.3 ± 66.7 |